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Abstract
Tumor hypoxia is one of the most important parameters that determines treatment sensitivity and is mainly due to
insufficient tumor angiogenesis. However, the local oxygen concentration in a tumor can also be shifted in response to
different treatment modalities such as cytotoxic agents or ionizing radiation. Thus, combined treatment modalities
including microtubule stabilizing agents could create an additional challenge for an effective treatment response due to
treatment-induced shifts in tumor oxygenation. Tumor hypoxia was probed over a prolonged observation period in
response to treatment with different cytotoxic agents, using a non-invasive bioluminescent ODD-Luc reporter system, in
which part of the oxygen-dependent degradation (ODD) domain of HIF-1a is fused to luciferase. As demonstrated in vitro,
this system not only detects hypoxia at an ambient oxygen concentration of 1% O2, but also discriminates low oxygen
concentrations in the range from 0.2 to 1% O2. Treatment of A549 lung adenocarcinoma-derived tumor xenografts with the
microtubule stabilizing agent patupilone resulted in a prolonged increase in tumor hypoxia, which could be used as marker
for its antitumoral treatment response, while irradiation did not induce detectable changes in tumor hypoxia. Furthermore,
despite patupilone-induced hypoxia, the potency of ionizing radiation (IR) was not reduced as part of a concomitant or
adjuvant combined treatment modality.
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Introduction
Hypoxia is one of the most important parameters that cause
enhanced tumor aggressiveness and treatment resistance, and
hypoxia is now considered to be an independent prognostic
indicator of poor outcome for different tumor entities. Alternating
periods of hypoxia and normoxia in the tumor support the
selection of tumor cells with elevated mutation frequency with
a more stress resistant and aggressive phenotype. Independent of
the cellular genotype, hypoxic cells are more treatment resistant
than normoxic cells, in particular towards ionizing radiation (IR).
Irradiation of cells leads to the formation of reactive oxygen
species (ROS), which induce cytotoxic DNA damage. Further-
more the oxygenation fixation theory implies that radiation-
induced free radical sites in the DNA are chemically derivatized
(‘‘fixed’’) in the presence of oxygen so that they can not be repaired
and accumulate, leading to an enhanced rate of cell death.
Thereby, normoxic cells are two- to three-fold more radiation
sensitive than cells under hypoxia [1,2].
Tumor hypoxia is mainly caused by insufficient tumor
angiogenesis and oxygen supply during tumor growth, however,
the oxygen content in a tumor can also be shifted in response to
different treatment modalities such as cytotoxic agents acting on
the tumor vasculature. Therefore, the combination of cytotoxic
agents, provoking an increase in tumor hypoxia, with ionizing
irradiation may impact treatment efficiency. We previously
investigated various combined treatment modalities with regard
to changes in tumor hypoxia, e.g. VEGF-receptor tyrosine kinase
inhibitors in combination with IR [3,4]. Furthermore, the tumor-
and tumor vasculature targeting, clinically relevant microtubule
stabilizing agent (MSA) patupilone (epothilone B) induced an at
least additive antitumoral effect when combined with IR [5,6]
raising the question on the dynamics of patupilone-induced
hypoxia and the combination scheduling with IR.
MSAs belong to the most important classes of anti-cancer agents
with taxanes being approved for a broad range of indications
including single treatment for non-small cell lung carcinoma or
advanced breast cancer [7,8]. The epothilones are nontaxoid
macrolide MSAs of bacterial origin, which share the same binding
site on b-tubulin (in close proximity to residue Thr274) with
taxanes [9,10,11]. Clinically different epothilone derivatives are
currently in various stages of development as antitumor com-
pounds [12]. Ixabepilone (IxempraH) is the first approved
compound in this class and indicated as monotherapy or in
combination with capecitabine for the treatment of patients with
metastatic breast cancer. Apart from a manageable safety profile,
ixabepilone demonstrates anti-tumor activity after failure and
resistance towards anthracycline and taxane standard therapy
[13].
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Epothilone B (patupilone) was tested as a phase III mono-
therapy agent against ovarian cancer and other epothilones are
undergoing a wide spectrum of single and combined treatment
modality in phase II studies (e.g. for recurrent glioblastoma, CNS
metastases from breast cancer, prostate, cervical, renal cell, gastric
and lung tumors, as well as non-Hodgkin’s Lymphoma (www.
cancer.gov) [13,14,15,16,17].
MSAs impair the dynamics of the microtubule network, leading
to defective mitotic spindle formation and accumulation of cells in
the G2/M-phase of the cell cycle [11,18] or at low concentrations
to transient G1- and S-phase arrest [5,19], followed by apoptosis-
induction [20]. An MSA-altered microtubule network also reduces
the cellular migration and invasion capacity [21,22]. Furthermore,
the potential of MSAs to accumulate cells in the radiosensitive
G2/M phase renders them potent sensitizers [23] for the
combined treatment with ionizing radiation [5,6,24].
The hypoxia-inducible transcription factor HIF-1 is a hetero-
dimer composed of an oxygen-sensitive alpha subunit and
a constitutively expressed beta subunit. HIF-1 binds to the
hypoxia response element (HRE) in the promoter region of
diverse target genes such as VEGF and induces their expression
[25]. Under normoxic conditions the alpha subunit is hydroxyl-
ated on proline402 and proline564 in the oxygen-dependent
degradation (ODD)-domain of HIF-1a by prolyl hydroxylase
domain (PHD) proteins. Proline hydroxylation leads to the
recognition by the von Hippel-Lindau tumor suppressor and
subsequent ubiquitination and proteasomal degradation [26].
Tumor hypoxia has previously been probed using different
luciferase-based bioimaging reporter constructs, which are either
based on luciferase expression under the control of an HRE-based
promoter system or on the fusion of extended or shorter ODD-
domains to the reporter gene [27,28,29]. The HRE-based
approach depends on intact HIF-signaling, however, several
classes of antisignaling agents including microtubule stabilizing
agents interfere with the activity of HIF-1-upstream elements or
the direct expression of HIF-1, independent of the pO2
[6,30,31,32,33,34]. We therefore did not use an HRE-based but
a minimal ODD-based in vivo bioimaging reporter approach,
which demonstrated high sensitivity even in the range of low pO2-
levels, to serially probe the dynamics of tumor hypoxia in response
and in relation to the antitumor effect of the microtubule
stabilizing agent patupilone and ionizing radiation, alone and as
part of the combined treatment modality.
Materials and Methods
Cell Culture
The human colon carcinoma cell line HCT116 was obtained
from Bert Vogelstein [35] and the lung adenocarcinoma cell line
A549 from Susan Band Horwitz [36]. All cell lines were kept at
37uC in 5% CO2. The cell line HCT116 was grown in McCoy
medium containing 10% (v/v) fetal bovine serum, 100 U/ml
penicillin and 100 mg/ml streptomycin. The cell line A549 was
grown in RPMI 1640 containing 10% (v/v) fetal bovine serum,
100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-
glutamine. Patupilone (epothilone B, EPO906) was provided by
the chemistry department of Novartis Pharma AG (Basel,
Switzerland).
Vector Construction
The plasmid SV40-pGL4.27 was obtained by inserting the
SV40 promoter of pGL3control (Promega Corporation, Madison,
WI, USA), cut with the restriction enzymes KpnI and HindIII,
into the pGL4.27 vector (Promega Corporation) containing the
luciferase gene including a 39PEST sequence for rapid degrada-
tion and turnover of the luciferase protein. An additional NarI
restriction site was inserted in the pGL4.27 plasmid at position 174
by site directed mutagenesis. The ODD-domain of HIF-1a was
amplified by PCR from the pcDHIF plasmid (kindly provided by
R.Wenger) as described in Safran et al, 2005 [37]. The product
was cloned into the pGL3 basic vector (by HindIII and NarI) and
finally inserted into the SV40-pGL4.27 vector, containing the
additional NarI-site, to obtain the vector construct SV40-ODD-
pGL4.27. To obtain the plasmids SV40-pGL4.26 and SV40-
ODD-pGL4.26, the SV40 promoter or the SV40-ODD sequence
was subcloned from the respective pGL4.27 plasmids cut by KpnI
and BsrG1 into the pGL4.26 backbone (Promega Corporation).
Stable Transfection, Reporter Gene Assay and Western
Blot Analysis
HCT116 cells were stably transfected with the SV40-ODD-
pGL4.27 plasmid and the A549 cells were stably transfected with
the SV40-ODD-pGL4.26 or the SV40-pGL4.26 plasmid by
lipofection (LipofectamineTM 2000 system; Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s instruction. Stable single
clones from hygromycin selected pools were selected for the
highest induction of luciferase activity after 8 hours incubation
under hypoxic conditions. The reporter gene assay was performed
as described by Rohrer Bley et al, 2009 [6]. Hypoxic conditions
were mimicked by the prolyl hydroxylase inhibitor dimethylox-
alylglycine (DMOG) (Biomol GmbH, Hamburg, Germany) at
a concentration of 0.25 mM or CoCl2 (0.25 mM). Alternatively,
cells were incubated under different pO2 in the hypoxic chamber
(Invivo2 400 hypoxia workstation, Biotrace International,
Bridgend, UK). Cells were allowed to attach for 8–10 hours
before addition of patupilone. Hypoxic conditions were applied 24
hours after patupilone treatment and luciferase activity was
determined 8 hours thereafter. Western blot analyses were
performed as described by Rohrer Bley et al, 2011 [38].
Clonogenic Cell Survival Assay
Clonogenic survival was determined by the ability of single cells
to form colonies in vitro. The number of plated cells was adjusted to
obtain ,100 colonies per cell culture dish with a given treatment.
After treatment with the different regimes, the dishes were
maintained at 37u in 5% CO2 and allowed to grow for 12 days
before fixation in methanol/acetic acid (3:1) and staining with
crystal violet. Cells were either preincubated with patupilone for
18 hours followed by irradiation, or preincubated with patupilone
for 18 hours followed by 7 days of cultivation in new media,
reseeded and irradiated on day 9, or preincubated with patupilone
for 8 days (in patupilone containing media), reseeded and
irradiated on day 9. Colonies with .50 cells/colony were counted
manually. All assays were repeated as independent experiments at
least thrice.
Hypoxyprobe-1 Immunofluorescence
A549 cells were seeded on glass cover slips and allowed to
attach overnight. Medium was exchanged and cells were
incubated with 150 mM hypoxyprobe-1 (HPI, Burlington, MA,
USA) for 3.5 hours under normoxic or hypoxic conditions.
Culture slides were washed with phosphate buffered saline
(PBS), fixed in 4% formaldehyde for 10 minutes at RT. Cells
were washed and permeabilized with 0.2% Triton X-100 buffer
on ice for 10 minutes. Cells were washed and autofluorescence
was quenched with 0.3 M glycin for 5 minutes. After
preincubation with 3% BSA in PBS at RT for 30 minutes,
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cells were incubated with the fluorescein isothiocyanate (FITC)-
labeled monoclonal anti-Hypoxyprobe-1 monoclonal antibody
(mAb1) in 3% BSA/PBS, (HPI), at RT in the dark for 1 hour.
DNA was counterstained with DAPI (1:2500 DAPI stock
solution (1 mg/ml) in PBS Sigma) for 15 minutes at RT. Cells
were finally washed with PBS. Images were captured by
fluorescence microscopy using a CCD camera (Leica
DM6000B equipped with Leica CTR6000).
Tumor Xenograft in Nude Mice and Application of
Treatment Regimes
Stably transfected HCT116 cells (46106) and A549 cells
(76106) were subcutaneously injected on the back of 4- to 8-
week old athymic nude mice. Tumors were allowed to expand
to a volume of 300 mm3 (610%) or 200 mm3 (610%) before
treatment start. Tumor volumes were determined as described
elsewhere [6]. The group sizes ranged from n= 7–12 for the
HCT116-xenograft experiments, from n= 3–5 for the A549-Luc
only and CoCl2-control experiments, and n= 5–16 for all other
experiments. Patupilone (dissolved in 30% PEG-300/70%
saline) was applied i.v. at a concentration of 2 mg/kg and
CoCl2 (45 mg/kg, dissolved in saline) i.p. after the first IVIS
measurement (day 0). Control mice were treated i.v. or i.p. with
saline. IVIS measurements were performed daily at the
indicated time points. Fractionated irradiation (361 Gy on 3
consecutive days) was applied locally using a customized led
shielding device with a Gulmay 200 kV X-ray unit at 1 Gy/
min.
Statement of Ethical Approval
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Swiss Cantonal Veterinary Authorities.
The protocol was approved by the Committee of the Swiss
Cantonal Veterinary Authorities (Permit Number: 136/2008 and
154/2011). All procedures and measurements were performed
under isoflurane anesthesia, and every effort was made to
minimize suffering.
In vivo Bioluminescence Imaging and Analysis
Mice were i.p. injected with 150 mg/kg D-luciferin (CaliperLife
Sciences, Hopkinton, MA, USA) (10 ml/g of a 15 mg/ml stock
solution) prior to anesthesia. Sequential measurements of light
emission (total flux) were taken approx. 5 minutes after D-luciferin
injection with the IVIS200 (CaliperLife Sciences). The measure-
ment with the highest total flux in the respective region of interest
(ROI), within the sequential measurement of each day and mouse,
was used for the longitudinal survey. The values were normalized
to day 0 and divided by the tumor volume to correct for treatment-
dependent changes.
Statistical Analysis
In vitro data presented are representatives of three or more
independent experiments, if not otherwise indicated. Student’s t-
test was used to evaluate the differences between normoxic and
hypoxic (incl. DMOG and CoCl2) conditions. Statistical analysis
of the in vivo tumor growth and luciferase activity data was
performed with the Mann-Whitney U test. The relative tumor
growth delay and the fold induction of luciferase activity/tumor
volume were normalized to day 0. The level of significance was
set at 0.05; the calculations were all performed using the
GraphPad Prism software version 5 (GraphPad Software Inc.).
Results
Establishment and Evaluation of a Highly Sensitive
in vitro and in vivo Tumor Hypoxia Reporter System
To monitor changes in tumor hypoxia in vivo, a reporter gene
system was constructed, which consists of an oxygen-dependent
degradation (ODD) domain fused 59 to the luciferase reporter
gene (ODD-Luc). This construct is constantly expressed in cells
under control of a minimal, hypoxia-independent, SV40-promoter
to be rapidly degraded under normoxic conditions, and slightly
differs from previously used ODD-based constructs [29,39]. The
ODD-sequence derives from the originally-identified human
oxygen-dependent degradation domain (ODD) of HIF-1a but
includes only the sequence coding for aa530 to aa652. This shorter
ODD includes proline564, which is hydroxylated under normoxia
and thereby marked for ubiquitin-dependent degradation by the
VHL-proteasome-pathway, but excludes the NO-sensitive Cys-
residue at amino acid position 520 (corresponding to mouse HIF-
1a aa533), which could lead to a hypoxia-independent stabiliza-
tion of the reporter construct in the presence of tumor associated
macrophages [39]. A luciferase reporter construct without an
ODD and under control of the same SV40-promoter served as
control system (Figure 1A).
Hypoxia-sensitivity of the ODD-luciferase reporter construct
was probed in stably-transfected A549 non-small cell lung cancer
cells under hypoxia and hypoxia-mimicking conditions using the
specific prolyl hydroxylase domain (PHD) inhibitor dimethylox-
alylglycine (DMOG) at non-toxic conditions. Western blot analysis
of cell lysates derived from cells incubated under normoxic and
hypoxic conditions (0.2% O2) or with DMOG (0.25 mM) revealed
high hypoxia- and DMOG-dependent protein levels of the ODD-
luciferase construct. Prolonged expression level of the construct
was observed under permanent hypoxic conditions but the ODD-
luciferase expression level decreased over time in DMOG-treated
cells (Figure 1B). This might be due to a reduced potency of
DMOG to constantly inhibit related PHDs. HIF-1a protein
stability paralleled ODD-luciferase protein levels under these
conditions but also decreased over time, most probably due to
a previously described regulatory feedback mechanism [40]. An
in vitro luciferase activity assay also clearly demonstrated a signif-
icantly strong hypoxia and DMOG-dependent increase in
luciferase activity in this stably transfected tumor cell line
(Figure 1C, p,0.005).
The kinetics of ODD-luciferase activity was further investigated
after cellular treatment with DMOG during a 22-hours time
course experiment and demonstrated the highest fold-increase in
ODD-luciferase activity 8–10 hours after PHD-inhibition, with
a subsequent slow decrease of luciferase activity over time
(Figure 1D). Keeping cells under hypoxia for 8 hours followed
by full reoxygenation to aerated conditions resulted in a rapid
decrease of luciferase activity within the first 20 minutes, to reach
50% of its activity under hypoxic conditions already 90 minutes
after reoxygenation (Figure 1E).
To validate this non-invasive ODD-luciferase reporter system
in vivo, we used cobalt salt CoCl2, which also inhibits PHDs. CoCl2
(0.25 mM) induced a time-dependent increase in HIF-1a and
ODD-luciferase protein levels in vitro (Figure 2B), and cellular
luciferase activity peaked 14 hours after addition of CoCl2
(Figure 2A, p,0.007). Mice carrying tumor xenografts, which
derived from ODD-Luc stably transfected A549 cells, were treated
with CoCl2 (45 mg/kg, i.p.), and luciferase activity in the tumor
xenograft was determined 14, 22 and 38 hours after CoCl2-
treatment by in vivo bioimaging. Luciferase activity significantly
increased in the tumor xenografts after CoCl2-treatment, reached
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a maximum of 2.5-fold induction at the 14 hour time point after
treatment (p,0.05) and returned to basal levels 38 hours after
treatment start. In comparison, luciferase activity in placebo-
treated control mice did not change over this 38 hour period
(Figure 2C and D).
To determine the sensitivity of the luciferase reporter system
towards different levels of hypoxia, stably-transfected A549 cells
were incubated for 8 hours at 0.2, 0.5, 1 and 2% O2. Interestingly,
the luciferase activity constantly increased with cellular incubation
at lower pO2-levels. An 8-fold increase in luciferase activity from
normoxia to 0.2% O2 and a 2.8-fold increase in luciferase activity
from 1% to 0.2% O2 was observed (p,0.01), which indicate a high
sensitivity towards different levels of hypoxia (Figure 3A).
The bioreductive hypoxia marker pimonidazole (Hypoxyp-
robe-1) forms stable adducts with thiol (sulphydryl) groups in
proteins below the threshold of 10 mmHg pO2, corresponding
to approx. 1.5–2% O2. To analyze whether different low levels
of pO2 can be distinguished from each other by an increased
cellular accumulation of pimonidazole, A549 cells were in-
cubated with pimonidazole (150 mM) under normoxia and
various concentrations of O2 (0.2, 0.5, 1, 2 and 5% O2) for 3.5
hours and stained with an FITC-labeled anti-pimonidazole
antibody. The staining intensity of pimonidazole increased in
a dose dependent way from normoxia to 2% O2, however no
difference in the staining intensity could be detected below 1%
O2 (Figure 3B).
Figure 1. Oxygen-sensitive luciferase reporter system. (A) Scheme of luciferase constructs for constitutive (Luc) and oxygen-sensitive
luciferase expression (ODD-Luc), containing a part of the oxygen-dependent degradation (ODD) domain of HIF-1a. Both constructs are under the
control of a minimal SV40-promoter. (B) Protein levels of HIF-1a and ODD-luciferase in cellular extracts of stably transfected A549 cells, incubated for
different time periods under normoxia, 0.2% O2 or DMOG. (C) Luciferase activity in stably transfected ODD-Luc A549 cells. Cells were incubated for 8
hours under normoxia, DMOG or hypoxia. (D) Luciferase activity in DMOG-treated, stably transfected ODD-Luc A549 cells over a 22 hour period. (E)
Luciferase activity in stably transfected ODD-Luc A549 cells kept for 8 hours under hypoxia and reoxygenated (time point 0 minutes) thereafter. Error
bars represent mean 6SE.
doi:10.1371/journal.pone.0051476.g001
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Overall these in vitro and in vivo results obtained with the non-
invasive ODD-Luc-reporter approach demonstrate the high
practicability and sensitivity to monitor dynamic changes in tumor
hypoxia in vitro and in vivo.
Changes in Tumor Hypoxia as Marker for Treatment
Response to Cytotoxic Agents
Using logistically-demanding non-invasive small animal posi-
tron emission tomography and classic invasive immunohistochem-
ical approaches, we previously demonstrated that cytotoxic, anti-
signaling and anti-angiogenic agents affect the tumor microenvi-
ronment and thereby tumor hypoxia [3]. In the intracellular
signaling-based bioluminescence reporter system used in this
report, which has been designed to investigate the dynamics of
tumor hypoxia under different treatment modalities, the level of
reporter gene expression and activity must be virtually indepen-
dent of direct interference with the agent of interest (see
introduction). To control for such a putative, detrimental in-
terference, luciferase activity in the human A549 lung adenocar-
cinoma and the human HCT116 colon adenocarcinoma cell line,
both stably transfected with the ODD-Luc-construct, was de-
termined in vitro on treatment with increasing concentrations of
patupilone under normoxic and hypoxic conditions. Hypoxia
significantly increased luciferase activity in both cells lines
(p,0.01) but cellular treatment with increasing concentrations of
patupilone did not perturb luciferase activity significantly neither
under normoxic nor hypoxic conditions (Figure 4A).
Having in hand a sensitive system to probe tumor hypoxia
in vivo, the dynamics of tumor hypoxia in response to patupilone
treatment was monitored over a prolonged observation period.
Stably-transfected A549 ODD-Luc cells were subcutaneously
injected on the back of nude mice and tumors were allowed to
grow until a volume of 200 mm3+/210%. Mice were then treated
with patupilone as a single dose (2 mg/kg, i.v.) and luciferase
activity in control and patupilone-treated mice was determined
over 10 days by in vivo bioimaging. The basal level of luciferase
activity in A549 ODD-Luc xenografts was measured prior to
patupilone injection and treatment-dependent changes in lucifer-
ase activity were further corrected for treatment-dependent
changes in the tumor volume (see Material and Methods). A
significant increase in luciferase activity already occurred on day 4
in tumor xenografts of mice treated with patupilone in comparison
to placebo-treated mice and reached a maximal induction of
luciferase activity at day 10 after treatment (4.6-fold versus 0.8-fold
in control tumors, p,0.001) (Figure 4B). Patupilone-treatment
also significantly inhibited tumor growth during this observation
period (Figure 4B). Relative luciferase activity declined approxi-
mately 20 days after treatment, in mice probed over a prolonged
Figure 2. CoCl2 increases luciferase activity in A549 ODD-Luc cells in vitro and in vivo. (A,B) Luciferase-activity (A) and HIF-1a, and protein
levels of ODD-luciferase (B) of CoCl2 (0.25 mM)-treated, stably transfected ODD-Luc A549 cells, determined at the indicated time points. Error bars
represent mean 6SE. (C) Luciferase activity of A549 ODD-Luc-derived tumor xenografts in mice injected with CoCl2 (45 mg/kg) at time point 0 hour
and at the indicated time points thereafter. (nCoCl2 = 6; ncontrol = 4) Error bars represent mean 6SE. (D) Representative in vivo bioimages of untreated
and CoCl2-treated mice.
doi:10.1371/journal.pone.0051476.g002
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time period (data not shown). The ability of the ODD-Luc system
to serially probe the luminescence in individual mice under
treatment qualifies this system and demonstrates its robustness
(Figure S1).
Control experiments were performed with tumor xenografts
derived from A549 cells, which were stably-transfected with intact
ODD-luciferase construct or a luciferase construct lacking an
ODD-domain (Luc-only) (Figure S1A). With the latter construct,
interference of patupilone with the SV40 promoter or with D-
luciferin uptake and diffusion could be excluded. Tumors were
allowed to grow until a volume of 200 mm3+/210%, and mice
were treated with either placebo or patupilone (2 mg/kg). Growth
rate was similar for both A549 ODD-Luc and A549 Luc-only-
derived tumor xenografts, and patupilone induced a comparable
tumor growth delay for both tumor types. In contrast luciferase
activity only increased after patupilone treatment in tumors
derived from the ODD-Luc expressing A549 cells. These results
further corroborate the specificity of the hypoxia-reporter
construct to monitor treatment-related changes in vivo (Figure 4C).
To test for patupilone-increased tumor hypoxia in other tumor
cell systems, the human colorectal adenocarcinoma cell line
HCT116 was stably transfected with the ODD-Luc-construct and
xenotransplanted in nude mice. HCT116 ODD-Luc derived
tumors were allowed to grow to a volume of 300 mm3+/210%,
and mice were treated with placebo or a single dose of patupilone
(2 mg/kg). Tumor growth was significantly inhibited (p,0.005)
and luciferase activity also significantly increased in this tumor
model in response to patupilone treatment (p,0.01; day 2–9).
However, increase in luciferase activity already peaked on day 7
after patupilone treatment, though to a lesser extent in comparison
to the A549-derived tumor system (Figure 4D). Histologic-
morphologic analysis revealed a high percentage of necrosis
(.50%) in this tumor model, thus complicating tumor volume
standardization. Therefore, further experiments were only per-
formed with the A549-derived tumor model with a low level of
tumor necrosis.
Tumor hypoxia is an important parameter for tumor radiosen-
sitivity, and fluctuation of tumor hypoxia may influence the
treatment response to radiotherapy. Control experiments with
A549 ODD-Luc and A549 Luc-only cells performed in vitro under
normoxia and hypoxia-mimicking conditions (DMOG) revealed
that irradiation does not affect expression of these reporter
construct per se. Likewise irradiation did not change luciferase
activity in tumor xenografts expressing the Luc-only construct
(Figure S2). Short-term fractionated irradiation was therefore used
as a second cytotoxic treatment modality to probe the dynamics of
tumor hypoxia under treatment (Figure 5). A549 ODD-Luc-
derived tumor xenografts with a small or a large tumor volume
(200 mm3 and 400 mm3, respectively) were irradiated with
a minimally fractionated treatment regimen of 361 Gy on 3
consecutive days and luciferase activity was determined during
treatment and seven follow-up days. In the two control groups
covering small and large tumor volumes, tumors steadily increased
in size and volume-corrected luciferase activity did not change
over time (Figure 5B and D). The minimal irradiation regimen
suppressed tumor growth until day 8 after treatment start in the
Figure 3. Differential sensitivity for low levels of pO2 by ODD-luciferase and pimonidazole. (A) Luciferase activity in A549 ODD-Luc cells
was determined after cellular incubation for 8 hours at different levels of hypoxia and normoxia. Error bars represent mean 6SE. (B) Detection of
pimonidazole accumulation in A549 cells incubated at different levels of hypoxia and normoxia. Images display immunocytochemistry staining of
pimonidazole and DAPI for nuclear staining (magnification,6300).
doi:10.1371/journal.pone.0051476.g003
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Figure 4. Patupilone-dependent increase in tumor hypoxia in vivo. (A) Stably-transfected A549 ODD-Luc and HCT116 ODD-Luc cells were
treated with increasing concentrations of patupilone for 24 hours before incubation under normoxia and hypoxia (0.2% O2). Luciferase activity was
determined after 8 hours of hypoxia. Error bars represent mean6SE. (B) Luciferase activity (left side) and tumor growth (right side) of A549 ODD-Luc-
derived tumor xenografts in mice treated with patupilone (2 mg/kg). (ncontrol = 7; npatupilone = 19) (C) Luciferase activity and tumor growth of A549
ODD-Luc and A549 Luc-only-derived xenografts in mice treated with patupilone (2 mg/kg). (nODD-Luc = 5; nLuc = 3) (D) Luciferase activity and tumor
growth of HCT116 ODD-Luc-derived xenografts in mice treated with patupilone (2 mg/kg). (ncontrol = 7; npatupilone = 12) Error bars represent mean6SE
of fold induction luciferase activity/tumor volume or relative tumor volume per group.
doi:10.1371/journal.pone.0051476.g004
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group of small tumors, and during the entire observation period in
the group with large tumors (Figure 5A and C). Irradiation
induced a slight increase in luciferase activity in both groups (1.5 to
1.7-fold), which remained stable in the group of large tumors but
again decreased to basal level in the group of small tumors towards
the end of the observation period. Interestingly, this drop of
volume-corrected luciferase activity coincided with resumed tumor
growth and remained at basal levels during subsequent tumor
growth (data not shown).
Patupilone-induced Hypoxia does not Impair the
Radiation Response
We previously investigated the combined treatment modality of
patupilone and ionizing radiation and determined an at least
additive treatment response on concurrent treatment on A549,
SW480 colon carcinoma and D425Med medulloblastoma xeno-
grafts [5,6,41]. We now aimed to investigate the dynamics of
tumor hypoxia, as indicated by changes in luciferase activity, in
response to this combined treatment modality and to determine
a putative counteractive effect of patupilone-induced tumor
hypoxia on the radiation response. Therefore, A549 ODD-Luc-
derived tumor xenografts were treated with different treatment
schedules and luciferase-activity was monitored.
First, A549 ODD-Luc xenotransplanted mice at a small tumor
volume (200 m3) were treated with patupilone (2 mg/kg) and
ionizing radiation (361 Gy) as part of a concomitant treatment
regimen. In comparison to the intermediate treatment response to
IR and patupilone alone (see above), tumor growth was further
suppressed in response to the combined, concomitant treatment
modality already within this short observation period. Interesting-
ly, induction of luciferase activity in response to the combined
treatment modality was similar to the increase in luciferase activity
after patupilone-treatment alone and thus dominated over the
effect of luciferase activity after irradiation (Figure 6A).
Next, A549-ODD-Luc xenotransplants were treated with
placebo or patupilone alone (2 mg/kg) at a small tumor volume
(200 mm3) and were adjuvantly irradiated once the tumors
reached a volume of 400 mm3+/210% (in control and patupi-
lone-pretreated mice, which corresponds to the day of highest
patupilone-induced luciferase activity). Irradiation of placebo-
treated mice only resulted in a slight induction of luciferase-
activity, while irradiation of patupilone-pretreated mice further
enhanced the already elevated luciferase-activity twofold. In-
terestingly though, the IR-induced tumor growth delay was similar
in the placebo- and the patupilone-pretreated mice, despite the
elevated hypoxic status in the patupilone-pretreated tumors at the
time point of irradiation (Figure 6B). A differential tumor growth
delay between the two groups was also not revealed at extended
measurement times, during which the elevated luciferase activity
again decreased. Interestingly though, in vitro clonogenic survival
assays indicated that a prolonged pretreatment sensitizes to
ionizing radiation (Figure S3, S4).
Discussion
Radiosensitivity is progressively reduced when the pO2 in
a tumor is below 15–20 mmHg. PO2 determination with invasive
pO2 electrodes revealed a strong correlation between low pO2
Figure 5. Minimal effect of ionizing irradiation on tumor hypoxia. Luciferase activity and tumor volume of A549 ODD-Luc-derived xenografts
in control (B, D) and irradiated mice (A, C, 361 Gy) at a small (A, B, 200 mm3610%) and at a large (C, D 400 mm3610%) tumor volume at the day of
treatment start (nIR = 5; ncontrol = 7). Fold induction of luciferase activity per tumor volume (solid line) and relative tumor volume (dotted line) were set
to 1 at day 0. Error bars represent mean 6SE of fold induction luciferase activity/tumor volume or relative tumor volume per group.
doi:10.1371/journal.pone.0051476.g005
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prior treatment (,5–10 mmHg) and locoregional control after
radiotherapy in squamous cell cancer of the head and neck,
uterine cervix and non-small cell lung carcinoma [42,43,44,45,46].
However, the dynamics of tumor microenvironmental parameters
like hypoxia during treatment might even represent the better
prognostic factor with regard to clinical outcome [47]. Further-
more tumor microenvironment-interfering agents might also
negatively change tumor oxygenation and the hypoxic tumor
fraction by itself, thereby affecting the treatment response to
irradiation. Thus, a combined treatment modality might be
challenged by new potential hazards created by the combination
itself [3,6]. To address and investigate these processes and
endpoints, non-invasive methods are required that allow serial
determination of tumor hypoxia.
Here we established a non-invasive luciferase-based reporter
system to serially probe tumor hypoxia, and determined the course
of treatment-induced changes in tumor hypoxia in response to
ionizing radiation and the clinically relevant microtubule stabiliz-
ing agent patupilone. The fusion construct luciferase, linked to
a minimal ODD-domain, was stably expressed in tumor cells, but
rapidly degraded under normoxic conditions by the oxygen-
sensing prolyl hydroxylases. This hypoxia-sensing approach was
previously developed in mouse models, which express this fusion
protein ubiquitously and even as an ODD-luciferase transgene in
a spontaneous murine mammary carcinoma model [37,48]. Here
we demonstrate that this approach could also be easily adapted to
tumor xenografts in order to probe the effect of clinically relevant
antitumor treatment modalities on tumor hypoxia. In contrast to
HRE-based-luciferase hypoxia-reporting systems, the ODD-lucif-
erase system with a minimal ODD-domain has the advantage to
be robust against putative interference of agents of interest with
the signaling cascade upstream of HIF-1, thereby avoiding false
positive or negative readouts. Control experiments on the
expression level of prolyl hydroxylase 2 and 3 in the A549 tumor
cell line and in histological A549 ODD-Luc cell-derived tumor
sections did not reveal treatment-induced changes, which might
have influenced the reporter system (data not shown).
Our in vitro experiments revealed that the ODD-luciferase
hypoxia reporter systems can be used to sense and differentiate
decreasing O2-levels even as low as 0.2% O2. Thus, this approach
– at least in our cell system - is more sensitive than pO2-
measurements with the hypoxia marker pimonidazole, which did
not discriminate hypoxic milieus below 1.5% O2, corresponding to
10 mmHg, and more sensitive than 18F-fluoromisonidazole
(FMISO), which is used as hypoxia tracer for positron emission
tomography in experimental tumor models and which has similar
chemical properties as pimonidazole [49]. While the ODD-
luciferase reporter system is highly sensitive to detect tumor
hypoxia, unfortunately, the resolution of the in vivo bioimaging
system is rather low. Therefore, only collective luminescence
derived from the luciferase activity in the whole tumor could be
determined, representing the mean tumor oxygenation status in
the whole tumor. Thus, we could not distinguish between tumor
areas with high or low tumor hypoxia and could not identify
tumor sections that are specifically prone to treatment-induced
changes in tumor hypoxia. Future in vivo bioimaging approaches
with improved resolution are required to overcome these draw-
backs.
Figure 6. Tumor hypoxia in response to the combination of patupilone and ionizing radiation. (A) Luciferase activity and tumor growth
of A549 ODD-Luc-derived xenografts in response to patupilone (2 mg/kg, day 0) and ionizing radiation (361 Gy, day 1–3) alone and in combination,
treated at a tumor volume of 200 mm3610%. (ncontrol = 7; nIR = 5; npatupilone = 19; ncombined = 5) (B) Luciferase activity and tumor growth of A549 ODD-
Luc-derived xenografts in control and patupilone-pretreated mice. Irradiation was performed at a tumor volume of 400 mm3610% (control) or 10
days after patupilone-pretreatment, (ncontrol = 7; nIR = 5; npatupilone = 6; ncombined = 5). Data used in Figure 4 and 5 are replotted into this figure for
better comparison of the treatment groups. Error bars represent mean 6SE of fold induction luciferase activity/tumor volume or relative tumor
volume per group.
doi:10.1371/journal.pone.0051476.g006
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The dynamics of tumor hypoxia in tumor xenografts were
probed in response to minimal fractionated irradiation and the
microtubule stabilizing agent patupilone. Independent of the
initial tumor volume, irradiation resulted in a transient tumor
growth arrest with a slight increase in the hypoxic fraction
(volume-corrected luciferase activity). A drop in the hypoxic tumor
fraction 5 days after treatment end in tumors treated at a small
tumor volume coincided with resumed tumor growth, which could
be due to the recovery or normalization of the tumor vasculature.
We previously demonstrated that the hypoxic fraction in response
to low dose, fractionated irradiation changes only minimally, but
that the tumor vasculature nevertheless may undergo structural
changes (e.g. switch to intussusceptive angiogenesis) with full
recovery only after extended tumor regrowth [3,50].
Single treatment with patupilone resulted in extended tumor
growth arrest in both tumor models (A549, HCT116) and a strong,
prolonged increase in the hypoxic tumor fraction. This correlation
was accidentally confirmed in three (out of nineteen) patupilone-
non-responding animals on the level of tumor growth and tumor
hypoxia. No substantial patupilone-induced tumor growth delay
was observed in these three patupilone-treated xenografted mice,
and likewise, luciferase activity did not increase in these tumor
xenografts. We could not explain the lack of responsiveness in
these three mice, but more importantly they illustrate the
correlation between the anti-tumoral effect of patupilone and the
increase in intratumoral hypoxia in response to patupilone
treatment (data not shown).
Thus, an increase in tumor hypoxia could represent an early
surrogate marker for treatment sensitivity towards patupilone and
likewise towards other microtubule stabilizing agents. However,
we have only limited mechanistic insights how patupilone affects
tumor hypoxia. Patupilone has anti-angiogenic and vascular
disruptive activity leading to reduced tumor blood volume, which
finally could translate into enhanced tumor hypoxia [51].
Patupilone directly interferes with HIF-signaling, which eventually
results in a diminished tumor hypoxia stress response. Using
a genetically defined patupilone-sensitive and -resistant tumor
model, we previously demonstrated that the major cytotoxic insult
occurs on the tumor cell level, and that the anti-angiogenic effect
of patupilone required patupilone-dependent blockage of pro-
angiogenic cytokine expression and secretion from the targeted,
patupilone-sensitive tumor cell, such as VEGF [6,38]. Here,
histologic analysis of patupilone-treated tumors did not reveal
a significant additional increase in pimonidazole-staining in
comparison to the already intense pimonidazole-level for the
A549 control tumors. This might be due to lack of correlation
between HRE- or ODD-based bioimaging readouts and pimoni-
dazole-staining, as already observed by others [27,52], or the
already low pO2-levels present in the control tumors, which does
not allow anymore the use of pimonidazole to differentiate
between treatment-dependent changes in pO2-levels (see above).
Own studies revealed a supra-additive antitumoral effect of
patupilone in combination with ionizing radiation, against tumor
xenografts derived from different tumor cell lines [5,6,41]. We
previously demonstrated that ionizing radiation counteracted an
inhibitor-of-angiogenesis-induced increase in tumor hypoxia in
tumor xenografts when used as part of a combined treatment
modality and thereby counteracted the potential risk of enhanced
radiation resistance by the inhibitor of angiogenesis [3]. Concom-
itant treatment of patupilone with ionizing radiation did not
reduce the patupilone-dependent increase in tumor hypoxia.
Nevertheless, combined treatment resulted in an enhanced tumor
growth delay, which could be due to a synergistic insult to the
tumor cell compartment and tumor vasculature. Interestingly, the
hypoxic fraction in the patupilone-pretreated xenografts even
increased after adjuvant irradiation, which might derive from
persistent fragility of the tumor vasculature in patupilone-
pretreated xenografts and subsequent further damage on irradi-
ation. Nevertheless and despite the presence of an enhanced
hypoxic tumor fraction in the patupilone pretreated xenografts,
irradiation still induced a similar antitumoral effect in patupilone-
pretreated xenografts as in naive xenografts with a lower hypoxic
tumor fraction. A radiosensitizing level of patupilone might still be
present at the time point of irradiation, and indeed, in vitro
clonogenic survival assays indicated that only a prolonged
preincubation of cells sensitizes for ionizing radiation (Figure
S4). This could be due to an enhanced uptake of patupilone
overtime to high concentrations of patupilone, which eventually
could radiosensitize the cells. Thus, a patupilone-dependent
increase of tumor hypoxia might indeed nullify a putative
radioenhancing effect of patupilone, when irradiation is applied
at a later time point. Furthermore, we cannot rule out that
patupilone-enhanced tumor hypoxia might only become relevant
for higher single doses of ionizing radiation or for more extended
treatment schedules than the one used in our study. Future studies
including tumor control endpoints could resolve this issue prior to
clinical application.
Overall, our results obtained with the two anticancer agents
patupilone and ionizing radiation demonstrate, that the ODD-
luciferase reporter system is a highly convenient, non-invasive
approach to serially probe the dynamics of tumor hypoxia in
murine tumor xenograft models. Patupilone-induced increase in
tumor hypoxia might be used as marker for patupilone sensitivity.
Furthermore, scheduling-experiments of the treatment modality of
patupilone in combination with ionizing radiation reveal that
patupilone-induced tumor hypoxia does not enhance radiation
resistance as part of a concomitant or neo-adjuvant treatment
regimen.
Supporting Information
Figure S1 (A) Initial luciferase activity of A549 ODD-Luc and
A549 Luc-only-derived xenografts at a tumor volume of
200 mm3610%. (B+C) Luciferase activity per tumor volume of
individual A549 ODD-Luc mice treated with patupilone (2 mg/
kg) at 200 mm3610% (B) or the individual respective control mice
(C).
(TIF)
Figure S2 (A+B) Luciferase activity in stably transfected A549
ODD-Luc and A549 Luc-only cells, incubated for 8 hours under
normoxia or DMOG and irradiated 4 hours after addition of
DMOG. Error bars represent mean 6SE. (C) Luciferase activity
and tumor growth of HCT116 Luc-only derived xenografts in
mice, irradiated (363 Gy within 24 hours) at a tumor volume of
350–580 mm3 at the day of treatment start (n = 5). Fold induction
of luciferase activity per tumor volume (solid line) and relative
tumor volume (dotted line) were set to 1 at day 0. Error bars
represent mean 6SE of fold induction luciferase activity/tumor
volume or relative tumor volume.
(TIF)
Figure S3 Luciferase activity and tumor growth of A549
ODD-Luc-derived tumor xenografts in control and
patupilone-pretreated mice over a time period of 18
days. Irradiation was performed at a tumor volume of
400 mm3610% (control) or 10 days after patupilone-pretreat-
ment. (ncontrol = 7; nIR = 5; npatupilone = 6; ncombined = 5). Error bars
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represent mean 6SE of fold induction luciferase activity/tumor
volume or relative tumor volume.
(TIF)
Figure S4 Clonogenic cell survival after treatment with
patupilone and IR of A549 ODD-Luc cells. Cells were
treated with placebo or patupilone for 18 hours followed by an
immediate clonogenic survival assay in response to irradiation, or
preincubated with patupilone for 18 hours followed by 7 days of
cultivation in absence or presence of patupilone, followed by
a delayed clonogenic survival assay in response to irradiation.
Error bars represent mean 6SE.
(TIF)
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